Compare LEE & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEE | WHWK |
|---|---|---|
| Founded | 1890 | 2007 |
| Country | United States | United States |
| Employees | N/A | 23 |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.0M | 233.4M |
| IPO Year | 2025 | N/A |
| Metric | LEE | WHWK |
|---|---|---|
| Price | $9.23 | $4.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 68.2K | ★ 316.6K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $543,955,000.00 | N/A |
| Revenue This Year | $5.48 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.34 | $1.57 |
| 52 Week High | $11.88 | $5.50 |
| Indicator | LEE | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 41.24 | 57.28 |
| Support Level | $7.95 | $3.80 |
| Resistance Level | $9.44 | $5.35 |
| Average True Range (ATR) | 0.79 | 0.29 |
| MACD | -0.24 | 0.01 |
| Stochastic Oscillator | 8.62 | 71.60 |
Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.